Thats a good bit of broker research to look at ......
http://www.emergingbiotechstock.com/research-report
Here is an extract ..........
Significantly undervalued compared to similar companies that have NASH therapies in Phase II clinical trials. NASH therapies are estimated at a $40 billion global market by 2025 and significant valuations have been awarded to companies in phase II clinical trials for NASH. Intercept Pharmaceuticals had positive phase II results for its NASH therapy, leading to an increase in market cap from $1.5 billion to $6.6 billion. Immuron's phase II study is on track to report similar results for its NASH therapy. Also, Enanta Pharmaceuticals (market cap: $906 million) is currently in phase I clinical development for the treatment of NASH. We believe that a successful trial in NASH would lead to a significant gain in stock price for IMRN. The following peer chart shows the market caps of similar companies that have NASH therapies in phase 2 (Intercept Pharmaceuticals is in Phase 3)
Eventually the market will wake up to the potential value locked up in IMC
But I think most buyers need a sign saying " This stock will go up 10 - 20 fold"
Obviously there will never be such a sign ..... but the probability that little IMC could get seriously re rated gets larger every day I suspect
cheers
VA
Add to My Watchlist
What is My Watchlist?
